From thought-provoking keynote sessions to networking opportunities, AMCP CEO, Susan Cantrell, MHL, RPh, CAE, highlights what AMCP 2022 attendees can look forward to at the annual meeting.
On Feb. 14, AMCP joined a pharmacy stakeholder letter supporting Dr. Robert Califf's nomination for FDA Commissioner, a post he previously held in 2016.
On Feb. 9, AMCP submitted comments to CMS supporting the agency's proposal to cover anti-amyloid monoclonal antibodies through the Coverage with Evidence Development pathway.
On Jan. 11, CMS released a proposed coverage decision that would cover the costs of monoclonal antibody treatments for Alzheimer's Disease patients only if they are enrolled in clinical trials.
On Jan. 6, CMS released a proposed rule that would require pharmacy price concessions be passed to patients at the point-of-sale and reinstate detailed MLR reporting requirements.
On Dec. 28, CMS released a proposed rule that would, in part, propose that adverse tiering is presumptively discriminatory and require that QHP issues offer more standardized plan options.
AMCP has recently published a manuscript in the Journal of Managed Care + Specialty Pharmacy (JMCP) focusing on the significant role that health plans, managed care organizations, prescribers, pharmacists, patients, and others have in decreasing the morbidity and mortality associated with opioid overdose.